Novel and simple method of double‑detection using fluorescence in situ hybridization and fluorescence immunostaining of formalin‑fixed paraffin‑embedded tissue sections

Ikeda,Satoshi

doi:10.3892/ol.2017.7413

Novel and simple method of double‑detection using fluorescence in situ hybridization and fluorescence immunostaining of formalin‑fixed paraffin‑embedded tissue sections

Authors:
- Satoshi Ikeda
View Affiliations

Affiliations: Department of Pathology, Tsuchiura Kyodo General Hospital, Tsuchiura, Ibaraki 300‑0028, Japan
Published online on: November 15, 2017 https://doi.org/10.3892/ol.2017.7413
Pages: 1084-1088

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The importance of fluorescence in situ hybridization (FISH) for pathological diagnosis has been increasing. However, the procedures utilized for a conventional FISH method with formalin‑fixed paraffin‑embedded tissue sections are complicated and it is difficult to perform as a routine laboratory test. In addition, there are difficulties with differentiation of targeted cells in observations with a fluorescence microscope. The present study reported a novel method that utilizes FISH in combination with fluorescence immunostaining as a simple double‑detection technique that addresses these problems. Using this novel method, various genetic aberrations, as well as protein overexpression were easily visualized in isologous sections. In particular, FISH signals with our method clearly identify target cells in samples with poor differentiation between tumor cells coexisting with normal cells. It is proposed that this simple technique is widely applicable as a routine laboratory test and future developments are expected.

View Figures

View References

1	Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 25:118–145. 2007. View Article : Google Scholar : PubMed/NCBI
2	Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR and Ladanyi M: SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 338:153–160. 1998. View Article : Google Scholar : PubMed/NCBI
3	Moatamed NA, Nanjangud G, Pucci R, Lowe A, Shintaku IP, Shapourifar-Tehrani S, Rao N, Lu DY and Apple SK: Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer. Am J Clin Pathol. 136:754–761. 2011. View Article : Google Scholar : PubMed/NCBI
4	Japanese Society of Pathology, . Guideline for HER2 examination of gastric cancer and breast cancer. 1st. Kanehara Press Co.; Tokyo: 2015
5	Owens MA, Horten BC and Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 5:63–69. 2004. View Article : Google Scholar : PubMed/NCBI
6	Abaza HM, Youssef SR, Saad AA, Kamal GM, Hegazy MG, Ibrahim RI and Annaka LM: Detection of 14q32 rearrangements in multiple myeloma, using simultaneous FISH analysis combined with immunofluorescence. Hematol Oncol Stem Cell Ther. 8:56–63. 2015. View Article : Google Scholar : PubMed/NCBI
7	Weber-Matthiesen K, Winkemann M, Müller-Hermelink A, Schlegelberger B and Grote W: Simultaneous fluorescence immunophenotyping and interphase cytogenetics: A contribution to the characterization of tumor cells. J Histochem Cytochem. 40:171–175. 1992. View Article : Google Scholar : PubMed/NCBI
8	Weber-Matthiesen K, Deerberg J, Müller-Hermelink A, Schlegelberger B and Grote W: Rapid immunophenotypic characterization of chromosomally aberrant cells by the new FICTION method. Cytogenet Cell Genet. 63:123–125. 1993. View Article : Google Scholar : PubMed/NCBI
9	Nomoto J, Hiramoto N, Kato M, Sanada M, Maeshima AM, Taniguchi H, Hosoda F, Asakura Y, Munakata W, Sekiguchi N, et al: Deletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphoma. BMC Cancer. 12:4572012. View Article : Google Scholar : PubMed/NCBI
10	Mostegl MM, Richter B, Dinhopl N and Weissenböck H: Influence of prolonged formalin fixation of tissue samples on the sensitivity of chromogenic in situ hybridization. J Vet Diagn Invest. 23:1212–1216. 2011. View Article : Google Scholar : PubMed/NCBI
11	Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, et al: Analytical validation and interobserver reproducibility of EnzMet GenePro: A second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol. 29:1505–1511. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ni R, Mulligan AM, Have C and O'Malley FP: PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer. Appl Immunohistochem Mol Morphol. 15:316–324. 2007. View Article : Google Scholar : PubMed/NCBI
13	Reisenbichler ES, Horton D, Rasco M, Andea A and Hameed O: Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section. Am J Clin Pathol. 137:102–110. 2012. View Article : Google Scholar : PubMed/NCBI
14	Nitta H, Kelly BD, Padilla M, Wick N, Brunhoeber P, Bai I, Singh S, Ranger-Moore J, Bieniarz C, Tsuda H and Grogan TM: A gene-protein assay for human epidermal growth factor receptor 2 (HER2): Brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol. 7:602012. View Article : Google Scholar : PubMed/NCBI